The letter is in regards to certain disclosures made by the company on the ongoing USFDA audit of company's Unit-1 and observations made by the USFDA between the period 2019 to 2022, Aurobindo Pharma Ltd (APL) said in a regulatory filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g5Z0nQ1
via IFTTT
0 comments:
Post a Comment